Guangxi Wuzhou Zhongheng Group Co.,Ltd

600252

CNE0000015F9

Pharmaceuticals

End-of-day quote Shanghai S.E. Other stock markets 18:00:00 2024-07-16 EDT			5-day change	1st Jan Change
2.19 ^CNY	-0.90%		+1.39%	-12.75%

07-02	Tranche Update on Guangxi Wuzhou Zhongheng Group Co.,Ltd's Equity Buyback Plan announced on April 17, 2024.	CI
06-05	Zhongheng Group Secures Drug Registration Certificate for New Respiratory Drug	MT

Tranche Update on Guangxi Wuzhou Zhongheng Group Co.,Ltd's Equity Buyback Plan announced on April 17, 2024.

July 01, 2024

From April 16, 2024 to June 30, 2024, the company has repurchased 51,875,400 shares, representing 1.52% for CNY 121.17 million. With this, the company has completed the repurchase of 51,875,400 shares, representing 1.52% for CNY 121.17 million under the buyback announced on April 17, 2024.

Latest news about Guangxi Wuzhou Zhongheng Group Co.,Ltd

Tranche Update on Guangxi Wuzhou Zhongheng Group Co.,Ltd's Equity Buyback Plan announced on April 17, 2024.	07-01	CI
Zhongheng Group Secures Drug Registration Certificate for New Respiratory Drug	06-05	MT
Guangxi Wuzhou Zhongheng Group Co.,Ltd announces an Increase in Equity Buyback.	05-19	CI
Guangxi Wuzhou Zhongheng Group Co.,Ltd Reports Earnings Results for the First Quarter Ended March 31, 2024	04-29	CI
Guangxi Wuzhou Zhongheng Group Co.,Ltd commences an Equity Buyback for CNY 200 million worth of its shares, under the authorization approved on March 28, 2024.	04-16	CI
Guangxi Honggui Capital Operation Group Co.,Ltd. agreed to acquire 18% stake in Guangxi United Asset Management Co., Ltd from Guangxi Wuzhou Zhongheng Group Co.,Ltd for approximately CNY 190 million.	04-08	CI
Guangxi Wuzhou Zhongheng Group Co.,Ltd Reports Earnings Results for the Full Year Ended December 31, 2023	03-29	CI
Lummy Pharma Gets Nod to Raise Dosage of Gastric Drug	03-18	MT
Wuzhou Zhongheng’s Drug For Preventing Chemotherapy-Related Nausea Passes Consistency Test	11-10	MT
Sealand Securities Co., Ltd. announced that it has received CNY 3.192189985 billion in funding from a group of investors	11-09	CI
Guangxi Wuzhou Zhongheng Group Co.,Ltd Reports Earnings Results for the Nine Months Ended September 30, 2023	23-10-27	CI
Guangxi Wuzhou Zhongheng Group Co.,Ltd(XSSC:600252) added to S&P Global BMI Index	23-09-18	CI
Guangxi Wuzhou Zhongheng Group Co.,Ltd(XSSC:600252) added to FTSE All-World Index	23-09-18	CI
Wuzhou Zhongheng Gets Nod to Trial Ovarian Cancer Drug	23-09-15	MT
Guangxi Wuzhou Zhongheng Group Co.,Ltd Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-29	CI
Guangxi Wuzhou Zhongheng Receives 42 Million Yuan in Government Subsidy	23-08-17	MT
Guangxi Wuzhou Zhongheng Group Co.,Ltd Reports Earnings Results for the First Quarter Ended March 31, 2023	23-04-27	CI
Guangxi Wuzhou Zhongheng Group Co.,Ltd Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-28	CI
Restrictions on Guangxi Wuzhou Zhongheng Drugs in 2022 Chinese Drug Catalogue Amended	23-01-24	MT
Guangxi Wuzhou Zhongheng Group Co.,Ltd Reports Earnings Results for the Nine Months Ended September 30, 2022	22-10-28	CI
Guangxi Wuzhou Zhongheng Group Co.,Ltd Reports Earnings Results for the Half Year Ended June 30, 2022	22-08-26	CI
Guangxi Wuzhou Zhongheng Group Co.,Ltd(XSSC:600252) dropped from S&P Global BMI Index	22-06-20	CI
Guangxi Wuzhou Zhongheng Group Co.,Ltd(XSSC:600252) dropped from FTSE All-World Index	22-06-13	CI
Guangxi Wuzhou Zhongheng Group Co.,Ltd Reports Earnings Results for the First Quarter Ended March 31, 2022	22-04-29	CI
Guangxi Wuzhou Zhongheng Group Co.,Ltd Reports Earnings Results for the Full Year Ended December 31, 2021	22-04-17	CI

Chart Guangxi Wuzhou Zhongheng Group Co.,Ltd

Duration

Period

Chart Guangxi Wuzhou Zhongheng Group Co.,Ltd

More charts

Company Profile

GUANGXI WUZHOU ZHONGHENG GROUP CO., LTD is a China-based company, principally engaged in the manufacture of pharmaceuticals and food production. The Company's pharmaceuticals include cardiovascular drugs, medicine for bruises, gynecology medication and other general drugs. The Company also provides Chinese herbal jelly products, Chinese herbal beverages and others. The Company is also engaged in the development of real estate, including the development and sales of commercial housings and stores. The Company mainly conducts its businesses within domestic market and to overseas markets.

Sector

Pharmaceuticals

Calendar

2024-08-30 - Q2 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Sector Other Pharmaceuticals

	1st Jan change	Capi.
GUANGXI WUZHOU ZHONGHENG GROUP CO.,LTD	-12.75%	1.04B
ELI LILLY AND COMPANY	+55.35%	815B
NOVO NORDISK A/S	+32.22%	597B
JOHNSON & JOHNSON	-0.10%	377B
MERCK & CO., INC.	+15.47%	319B
ABBVIE INC.	+13.10%	310B
ASTRAZENECA PLC	+16.53%	247B
NOVARTIS AG	+14.53%	228B
AMGEN INC.	+16.54%	180B
PFIZER, INC.	+4.31%	170B